Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Hormonal Contraception

Hormonal Contraception

Hormonal Contraception: Explore the power of advanced AI-driven research on the diverse array of hormonal contraceptive methods.
Discover effective protocols across published literature, preprints, and patents, empowering your research to identify the most impactful contraceptive solutions.
PubCompare.ai delivers reproducible, accuarate findings to drive your work forward, revolutionizing the field of hormonal contraception.

Most cited protocols related to «Hormonal Contraception»

1
Prospective Cohort Study of Couples' Reproduction
Cited 38 times
The LIFE Study used a prospective cohort design suitable for following couples across sensitive windows of human reproduction and development. Specifically, couples interested in becoming pregnant in the next 2 months were recruited and followed until pregnant or up to 12 months of attempting pregnancy between 2005 and 2009. In addition, pregnant women were followed to delivery or through a pregnancy loss. The target population comprised individuals residing in four Michigan counties with reported exposure to persistent organochlorine chemicals (i.e. Berrien, Calhoun, Ingham, Kalamazoo) and 12 counties in Texas (i.e. Aransas, Brazoria, Calhoun, Chambers, Fort Bend, Galveston, Harris, Jefferson, Matagorda, Montgomery, Nueces and Orange) with presumed exposure to persistent environmental chemicals. By design, the targeted population comprising potentially exposed individuals and their partners was intended to be inclusive of couples irrespective of gynaecological and/or urological history who were interested in becoming pregnant apart from sterilised couples or those who were told by a physician that they could not achieve pregnancy without medical assistance. The inclusion criteria were: (a) married or in a committed relationship; (b) females aged 18–40 and males aged 18+ years; (c) able to communicate in English or Spanish; (d) self-reported menstrual cycles ranging from 21 to 42 days consistent with the fertility monitor's requirement; and (e) no hormonal birth control injections in the past 12 months, given the uncertain return of ovulation. Our a priori sample size was 500 couples powered to be able to detect a reduction in fecundity in relation to differences in environmentally relevant concentration of organochlorine chemicals. We used data from the New York State Angler Cohort Study for the range of power assumptions, as it is the only prospective time-to-pregnancy study that had individual serum organochlorine concentrations for participating women.12 (link)A different sampling framework was utilised in each geographical location to recruit individuals, given the absence of a uniformly available approach in each state for identifying and recruiting reproductive aged couples planning pregnancies. This provided a unique opportunity to assess the efficacy of sampling frameworks on recruitment. Specifically, the Texas site used the Texas Parks and Wildlife Department's angler database for recruitment, while the Michigan site used a commercially available marketing database – InfoUSA® – that utilised recruitment filters to identify individuals with fishing interests (e.g. fishing magazine subscriptions). The former sampling framework comprises all commercial and recreational fishing licences in Texas, and was stratified by licence type and census track to achieve diversity. As race and ethnicity are not reported in this registry, the North American Association of Central Cancer Registries Hispanic Identification Algorithm was used to help oversample on presumed Hispanic ethnicity. The InfoUSA® sampling framework was assessed in two Michigan counties and found to provide complete coverage of households based upon data from the 2000 Census assuming some level of migration. Additional efforts were undertaken to oversample under-represented minorities and individuals living in census tracts with low median household incomes (≥$40 000). Prior to mailing letters, contact information was updated with commercially available software (e.g. Telematch and Metronet).
Recruitment began with an introductory letter and study brochure mailed to targeted individuals followed by a telephone call within 2 weeks, at which time contacted individuals were screened for eligibility. Up to 10 follow-up telephone calls were placed at varying times and days to reach targeted individuals by two call centres (http://ppri.tamu.edu; http://www.rti.org) consistent with their established survey methods. Each partner of the couple was individually screened for enrolment even if that meant additional telephone calls. The contact information of eligible and preliminarily consenting couples was given to the research coordinators at each site, who then assigned interviewers to couples. In-home interviews and training sessions were scheduled at the couple's convenience. The LIFE Study was conducted between 2005 and 2009.
Louis G.M., Schisterman E.F., Sweeney A.M., Wilcosky T.C., Gore-Langton R.E., Lynch C.D., Barr D.B., Schrader S.M., Kim S., Chen Z, & Sundaram R. (2011). Designing prospective cohort studies for assessing reproductive and developmental toxicity during sensitive windows of human reproduction and development – the LIFE Study. Paediatric and perinatal epidemiology, 25(5), 413-424.
Publication 2011
Central American People Decompression Sickness Eligibility Determination Environmental Exposure Ethnicity Females Fertility Hispanic or Latino Hispanics Hormonal Contraception Households Inclusion Bodies Interviewers Males Malignant Neoplasms Menstrual Cycle Minority Groups Obstetric Delivery Ovulation Physicians Pregnancy Pregnant Women Reproduction Serum Target Population Woman
2
INTERGROWTH-21st Fetal Growth Study
Cited 26 times
INTERGROWTH-21st is a multicenter, multiethnic, population-based project, conducted between 2009 and 2014 in eight urban areas in eight different countries: the cities of Pelotas, Brazil; Turin, Italy; Muscat, Oman; Oxford, UK; Seattle, USA; Shunyi County, Beijing, China; the central area of the city of Nagpur (Central Nagpur), Maharashtra, India; and the Parklands suburb of Nairobi, Kenya13 (link). Its primary aim was to study growth, health, nutrition and neurodevelopment of fetuses from < 14 + 0 weeks' gestation to 2 years of age, using the same conceptual framework as the World Health Organization (WHO) Multicentre Growth Reference Study12 (link), in order to produce prescriptive growth standards to complement the existing WHO Child Growth Standards14 .
These urban areas had to be located at low altitude (≤ 1600 m) and women receiving antenatal care had to plan to deliver in these institutions or in a similar hospital located in the same geographical area, and there had to be an absence or low levels of major, known, non-microbiological contamination such as pollution, domestic smoke, radiation or any other toxic substances, evaluated during the study period at the cluster level using a data collection form specifically developed for the project15 (link). In the eight urban areas, we selected all institutions providing pregnancy and intrapartum care, in which > 80% of deliveries occurred.
To generate the CRL data for our stated aims, women with a singleton pregnancy that was conceived naturally were asked to participate in the Fetal Growth Longitudinal Study (FGLS), one of the three main components of the INTERGROWTH-21st Project, whose study methods have been described in detail elsewhere13 (link). Briefly, we recruited women from the selected populations with no clinically relevant obstetric or gynecological history, who met the entry criteria of optimal health, nutrition, education and socioeconomic status to create a group of affluent, clinically healthy women who were at low risk of intrauterine growth restriction and preterm birth. Recruitment occurred prospectively and consecutively at 9 + 0 to 13 + 6 weeks' gestation as estimated by LMP provided that: (1) the date was certain; (2) the agreement between LMP and CRL dating was ≤ 7 days; (3) the women had a regular 24–32-day menstrual cycle; and (4) they had not been using hormonal contraception or breastfeeding in the preceding 2 months. The women, who were all well-educated and living in urban areas, reported the date and certainty of their LMP at their first antenatal clinic visit in response to specific questions.
A single type of ultrasound machine (Philips HD-9; Philips Ultrasound, Bothell, WA, USA) with an abdominal probe was the machine of choice to measure CRL. However, as the first contact with the study often occurred at several different clinics in the geographical area, it was considered acceptable to use other, locally available, machines for the CRL measurement at the first antenatal visit only, provided that they were evaluated and approved by the study team. All 39 ultrasonographers at the eight study sites underwent rigorous training and standardization specifically for CRL measurement16 (link). In accordance with the study's quality-control protocol, they also submitted images of the CRL measurements, which were reviewed blindly by our collaborators at the Société Française pour l'Amélioration des Pratiques Echographiques. The ultrasonographers were only certified to measure CRL in the study if they demonstrated adequate knowledge of the study protocol and the quality of the images submitted for review was satisfactory17 (link).
CRL was measured once using strict techniques and imaging criteria18 (link). A discrepancy between GA based on LMP and that derived from CRL of more than 7 days was a reason to exclude the woman from the study. All women were then followed to delivery with standardized antenatal care evaluation and regular ultrasound scans every 5 ± 1 weeks.
The INTERGROWTH-21st Project was approved by the Oxfordshire Research Ethics Committee ‘C’ (ref: 08/H0606/139) and the research ethics committees of the individual participating institutions, as well as the corresponding regional health authorities in which the project was implemented.
Papageorghiou A.T., Kennedy S.H., Salomon L.J., Ohuma E.O., Cheikh Ismail L., Barros F.C., Lambert A., Carvalho M., Jaffer Y.A., Bertino E., Gravett M.G., Altman D.G., Purwar M., Noble J.A., Pang R., Victora C.G., Bhutta Z.A, & Villar J. (2014). International standards for early fetal size and pregnancy dating based on ultrasound measurement of crown–rump length in the first trimester of pregnancy. Ultrasound in Obstetrics & Gynecology, 44(6), 641-648.
Publication 2014
Abdomen Care, Prenatal Child Clinic Visits Ethics Committees, Research Fetal Growth Fetal Growth Retardation Fetus Hormonal Contraception Menstrual Cycle Muscle Rigidity Obstetric Delivery Poisons Pregnancy Premature Birth Radiation Smoke Ultrasonography Woman
3
INTERGROWTH-21st Fetal Growth Study Protocol
Cited 11 times
INTERGROWTH-21st was a multicentre, multiethnic, population based project, conducted between 2009 and 2014 in eight countries.35 (link) The project’s primary aim was to study growth, health, nutrition, and neurodevelopment from less than 14 weeks’ gestation to 2 years of age, using the same conceptual framework as the World Health Organization Multicentre Growth Reference Study.36
The details of population selection have been described elsewhere.35 (link)
37 (link) In brief, all institutions providing obstetric care in eight urban areas in Brazil, China, India, Italy, Kenya, Oman, UK, and USA, with no or low levels of major, known, non-microbiological contamination, were chosen as study sites. From these populations, healthy women with a naturally conceived singleton pregnancy, and who met the individual inclusion criteria, were prospectively recruited into the Fetal Growth Longitudinal Study, one of the main components of the INTERGROWTH-21st Project.
Gestational age was estimated on the basis of the last menstrual period provided that the date was certain, the woman had a regular 24-32 day menstrual cycle, she was not using hormonal contraception or breastfeeding in the preceding two months, and the estimated gestational age (based on the last menstrual period) agreed (within seven days) with a standardised measurement of fetal crown rump length at 9+0 to 13+6 weeks’ gestation.30 (link)
38 (link)
39 (link) Follow-up visits occurred every five weeks (within one week either side)—that is, possible ranges were 14-18, 19-23, 24-28, 29-33, 34-38, and 39-42 weeks’ gestation.
At each visit, dedicated research staff who had undergone rigorous training and standardisation used the same protocols at all sites. Staff measured SFH first before taking fetal ultrasound measurements. With the woman in the supine position, having emptied her bladder, SFH was measured with a non-elastic metric tape (Chasmors) provided to all sites. After the start of the tape was positioned with one hand over the upper border of the symphysis pubis bone, the tape was placed in a straight line over the uterus until loss of resistance was felt when reaching the fundus. With the cubital edge of the hand used to sustain the tape in place at the point of the fundus, the tape was turned so that the numbers were visible to record the value to the nearest complete half centimetre.35 (link)
The process was then repeated to obtain a second measurement. Although it was not possible to blind the research staff to the gestational age at each visit, all SFH measurements were taken in a blinded fashion to reduce expected value bias by turning the tape measure so that no numbers were visible during the examination.
According to prespecified criteria, we excluded pregnancies complicated by fetal death or congenital abnormality, catastrophic or severe medical conditions (such as cancer or HIV); those with severe unanticipated conditions related to pregnancy that needed admission to hospital (such as eclampsia or severe pre-eclampsia); and those identified during the study who no longer fulfilled the entry criteria (such as women who started smoking during pregnancy or had an episode of malaria).
Papageorghiou A.T., Ohuma E.O., Gravett M.G., Hirst J., da Silveira M.F., Lambert A., Carvalho M., Jaffer Y.A., Altman D.G., Noble J.A., Bertino E., Purwar M., Pang R., Cheikh Ismail L., Victora C., Bhutta Z.A., Kennedy S.H, & Villar J. (2016). International standards for symphysis-fundal height based on serial measurements from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project: prospective cohort study in eight countries. The BMJ, 355, i5662.
Publication 2016
Blindness Care, Prenatal Congenital Abnormality Eclampsia Elbow Feelings Fetal Death Fetal Growth Fetal Ultrasonography Gestational Age Hormonal Contraception Malaria Malignant Neoplasms Menstrual Cycle Menstruation Muscle Rigidity Population Group Pre-Eclampsia Pregnancy Pubic Bone Urinary Bladder Uterus Woman
4
Hormonal Contraception and HIV-1 Transmission
Cited 10 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
CD4+ Cell Counts Child Condoms Contraceptive Agents Contraceptive Effect Contraceptive Methods Contraceptives, Oral Females Genital Diseases Genitalia HIV-1 HIV Seropositivity Hormonal Contraception Human Herpesvirus 2 Male Circumcision Males Plasma Pregnancy Sexual Partners Transmission, Communicable Disease Ulcer Woman
5
Menopausal Hot Flash Clinical Trial
Cited 10 times
The trial was conducted at 4 MsFlash network sites (Appendix 1). Participants were recruited from July 2009 to June 2010, primarily by mass mailing to age-eligible women on purchased mailing lists or health-plan enrollment files. Eligible women were ages 40–62 years, in the menopause transition (amenorrhea >=60 days in the past year), or postmenopausal (>=12 months since last menstrual period or bi-lateral oophorectomy), or had a hysterectomy with one or both ovaries remaining and FSH >20 mIU/mL and estradiol <=50 pg/mL; and were in general good health as determined by medical history, a brief physical exam and standard blood tests.
The required hot flash criteria were >=4 hot flashes or night sweats per day (24 hours) (an average of >=28 hot flashes/night sweats per week) recorded on daily hot flash diaries for 3 weeks in the screening period. Hot flashes/ night sweats had to be rated as bothersome (moderate or a lot) or severe (moderate or severe) on 4 or more days per week.
Exclusion criteria included use of psychotropic medications, prescription, over-the-counter, or herbal therapies for hot flashes in the past 30 days; hormone therapy, hormonal contraceptives, selective estrogen receptor modulators (SERMs) or aromatase inhibitors in the past 2 months; current severe medical illness, major depressive episode, drug or alcohol abuse in the past year; suicide attempt in the past 3 years; lifetime diagnosis of bipolar disorder or psychosis, uncontrolled hypertension, history of endometrial or ovarian cancer, myocardial infarction, angina or cerebrovascular events or lack of non-hormonal contraception if sexually active and not postmenopausal.
Freeman E.W., Guthrie K.A., Caan B., Sternfeld B., Cohen L.S., Joffe H., Carpenter J.S., Anderson G.L., Larson J.C., Ensrud K.E., Reed S., Newton K.M., Sherman S., Sammel M.D, & La Croix A.Z. (2011). Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA : the journal of the American Medical Association, 305(3), 267-274.
Publication 2011
Abuse, Alcohol Angina Pectoris Aromatase Inhibitors Bipolar Disorder Contraceptive Agents Diagnosis Drugs, Non-Prescription Endometrium Estradiol Health Planning Hematologic Tests High Blood Pressures Hormonal Contraception Hormones Hot Flashes Hysterectomy Menopause Menstruation Myocardial Infarction Ovarian Cancer Ovariectomy Ovary Pharmaceutical Preparations Physical Examination Phytotherapy Psychotic Disorders Psychotropic Drugs Selective Estrogen Receptor Modulators Suicide Attempt Sweat Therapeutics Woman

Most recents protocols related to «Hormonal Contraception»

1
INTERGROWTH-21st: Comprehensive Fetal Growth Study
INTERGROWTH-21st was a multicentre, multiethnic, population-based project, conducted between 2009 and 2014 in eight countries. The primary aim was to study growth, health, nutrition, and neurodevelopment from less than 14 weeks’ gestation to 2 years of age. Details of the study have been described elsewhere23 (link)–25 (link). In brief, all institutions providing obstetric care in eight geographically diverse regions in Brazil, China, India, Italy, Kenya, Oman, UK, and USA were chosen as study sites. From these, healthy women with a naturally conceived, singleton pregnancy who were at low risk of adverse maternal and perinatal outcomes were prospectively enroled into FGLS, one of the main components of INTERGROWTH-21st. GA was estimated from the LMP provided that: (a) the date was certain; (b) the woman had a regular 24–32 day menstrual cycle; (c) she had not been using hormonal contraception or breastfeeding in the preceding 2 months, and (d) any discrepancy between the GAs based on LMP and CRL, measured by ultrasound at 9+0 to 13+6 weeks from the LMP was ≤7 days26 (link).
Trained, dedicated research sonographers performed ultrasound scans every 5±1 weeks using identical equipment at all sites (Philips HD9 [Philips Ultrasound, Bothell, WA, USA] with curvilinear abdominal transducers C5–2, C6-3, V7-3). We used stored images of the three standard anatomical planes: (a) fetal head in the axial view at the level of the thalami, as required for measurement of the HC; (b) abdomen in an axial view at the level of measurement of the AC, and (c) femur in the longitudinal view used for measuring FL. The detailed measurement protocol, training, standardisation, and quality-control methods, including quality scoring of images, used across all study sites are described in detail elsewhere25 (link),27 (link),28 (link) and all documentation, protocols, data collection forms, and electronic transfer strategies are freely available on the INTERGROWTH-21st website.
Lee L.H., Bradburn E., Craik R., Yaqub M., Norris S.A., Ismail L.C., Ohuma E.O., Barros F.C., Lambert A., Carvalho M., Jaffer Y.A., Gravett M., Purwar M., Wu Q., Bertino E., Munim S., Min A.M., Bhutta Z., Villar J., Kennedy S.H., Noble J.A, & Papageorghiou A.T. (2023). Machine learning for accurate estimation of fetal gestational age based on ultrasound images. NPJ Digital Medicine, 6, 36.
Publication 2023
Abdomen Care, Prenatal Electron Transport Femur Head Hormonal Contraception Menstrual Cycle Mothers Pregnancy Thalamus Transducers Ultrasonography Woman
2
Survey of Reproductive Health in Italian Women

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Emergencies Endometriosis Genitalia Hormonal Contraception Hormones Hypomenorrhea Menopause Menstrual Cycle Pandemics Pelvic Diaphragm Pelvic Inflammatory Disease Polycystic Ovary Syndrome Polyps Pregnancy Reproduction Uterine Fibroids Vaginitis Woman
3
Improving Reproductive Health in SUD Recovery
SexHealth Mobile was implemented in partnership with a federally qualified health center (FHQC) in Kansas City that was already operating a MMU to provide basic health services at community locations with high need, including recovery centers. For this study, we selected three recovery centers that already partnered with the FHQC to receive periodic MMU visits for basic health services (e.g., seasonal vaccination, basic screenings, and treatment of non-emergency illness and injuries). The three recovery centers were providing services for clients with any type of SUD, most commonly polysubstance use disorders that included use of methamphetamines and/or opioids. Two centers were residential, serving individuals who had initiated recovery and were expected to not be using substances other than tobacco while in the program. The other was outpatient, serving individuals at various stages of recovery and active substance use. Prior to our intervention, the FHQC provided contraception and reproductive health services (free or discounted) at their main center, but not yet on the MMU.. Recovery centers did not routinely screen for reproductive health needs but would informally recommend community clinics (including the FHQC partner) for individuals interested in services.
Recovery center clients were eligible if they were: (1) aged 18–40; (2) screened positive for a lifetime history of problematic drinking or drug use according to CAGE-AID tool [24 ]; (3) able to become pregnant (assigned female sex at birth, pre-menopausal, not sterilized or diagnosed with infertility) but not currently pregnant; (4) not currently using an intrauterine device or hormonal contraception (i.e., oral contraceptive pill, transdermal patch, vaginal ring, injectable, subdermal implant); and (5) not previously enrolled in either phase of the study.
Hurley E.A., Goggin K., Piña-Brugman K., Noel-MacDonnell J.R., Allen A., Finocchario-Kessler S, & Miller M.K. (2023). Contraception use among individuals with substance use disorder increases tenfold with patient-centered, mobile services: a quasi-experimental study. Harm Reduction Journal, 20, 28.
Publication 2023
Anti-HIV Agents Childbirth Contraceptive Methods Contraceptives, Oral Females Hormonal Contraception Injuries Intrauterine Devices Methamphetamine Opioids Outpatients Premenopause Reproduction Reproductive Health Services Sterility, Reproductive Substance Use Tobacco Products Transdermal Patch Treatment, Emergency Vaccination
4
Postpartum Contraceptive Uptake Study
The primary outcome was use of IUD or hormonal contraception (pills, patch, ring, contraception injection, subdermal implant) at one-month post-enrollment. Secondary outcomes were use at two-weeks and three-months. We also explored group differences in confidence in preventing unintended pregnancy at post-intervention and as a change from baseline to post-intervention (reported on a repeated 5-point scale ranging from “not at all confident” to “extremely confident”) as well as reasons for non-use at one-month (including reasons for not attending clinic visits, picking up prescriptions, and/or starting birth control).
Hurley E.A., Goggin K., Piña-Brugman K., Noel-MacDonnell J.R., Allen A., Finocchario-Kessler S, & Miller M.K. (2023). Contraception use among individuals with substance use disorder increases tenfold with patient-centered, mobile services: a quasi-experimental study. Harm Reduction Journal, 20, 28.
Publication 2023
Clinic Visits Contraceptive Methods Contraceptives, Oral Hormonal Contraception Prescriptions Self Confidence
5
Integrating Contraceptive Care in Mobile Units for SUD Recovery
SexHealth Mobile is grounded in formative research and centered on reproductive justice and harm reduction principles. The intervention featured “SexHealth Mobile Days” where the MMU, clinical staff, and study staff would visit each recovery center. In preparation, we worked with the FHQC leadership and clinical staff to integrate contraceptive services within the MMU. This included one nurse practitioner with experience in patient-centered contraception care for SUD patients, one care assistant, and materials required for on-site provision of contraceptive medications (e.g., pregnancy tests, needles, syringes). The nurse practitioner (author AA) specialized in women’s health, independently placed contraceptive devices, and had worked at the partner FHQC for seven years (including previously providing general health care on the MMU). We worked with recovery centers and FHQC staff to ensure services were provided in a way that was acceptable to potential patients, including arranging for pregnancy testing with urine collected by patients themselves within recovery center facilities.
On SexHealth Mobile Days, the provider offered contraceptive options on the MMU free of charge, including hormonal (i.e., pills, transdermal patch, vaginal ring, injection, subdermal implant) and non-hormonal (diaphragm, condoms). Participants who chose short-term hormonal contraception (pills, patch, ring, injection) were given dosage for three months of pregnancy prevention and instructions for refills/follow-up at the main FQHC. The MMU was not outfitted with a standard patient exam table that could be used for gynecological procedures, thus we could not offer same-day IUDs. However, participants interested in IUDs could speak to the provider on the MMU, schedule a facility-based IUD insertion appointment at the main FHQC with the same provider, and obtain a bridging method to protect against pregnancy until IUD insertion. Further, participants interested in sexual and reproductive health services beyond contraception were also able to speak with the MMU provider and schedule appropriate facility-based FHQC appointments. Study staff also offered free condoms and home pregnancy tests at the enrollment table for anyone at the recovery center. We conducted ten SexHealth Mobile Days before reaching our target recruitment in intervention period, with four visits at the larger residential center, two at the smaller residential center, and four at the outpatient center.
At each recovery center, 2–4 individuals who already occupied formal roles as trusted resources for clients (7 peer mentors, 3 social workers) were trained as “outreach leaders” to promote SexHealth Mobile Days and organize interested clients. Training covered basic principles of reproductive justice and harm reduction, contraception options, needs and challenges faced by individuals with SUD in preventing unintended pregnancies, and strategies for using client-centered and trauma-informed approaches when talking about contraception.
Outreach leaders and study staff stressed that all activities on SexHealth Mobile Days were completely voluntary, and people could obtain a clinic referral or meet with MMU providers and receive free contraception even if they chose not to enroll in the study, or were not eligible due to previous enrollment in the EUC period or other ineligibility criteria. Individuals could also enroll in the study and meet with MMU providers even if they were unsure or not interested in taking up contraception.
Hurley E.A., Goggin K., Piña-Brugman K., Noel-MacDonnell J.R., Allen A., Finocchario-Kessler S, & Miller M.K. (2023). Contraception use among individuals with substance use disorder increases tenfold with patient-centered, mobile services: a quasi-experimental study. Harm Reduction Journal, 20, 28.
Publication 2023
Condoms Contraceptive Agents Contraceptive Devices Contraceptive Methods Contraceptives, Oral Harm Reduction Hormonal Contraception Mentors Needles Outpatients Patient-Centered Care Patients Practitioner, Nurse Pregnancy Pregnancy Tests Reproduction Reproductive Health Services Syringes Transdermal Patch Urine Vaginal Diaphragm Woman Wounds and Injuries

Top products related to «Hormonal Contraception»

1
Spss version 25 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
2
Pipelle aspirator by CooperSurgical
Sourced in United States
The Pipelle aspirator is a medical device used for the collection of endometrial tissue samples. It is a single-use, flexible plastic tube with a piston mechanism that is inserted into the uterus to gently suction and extract a small amount of the uterine lining for diagnostic purposes.
3
Stata version 11 by StataCorp
Sourced in United States, Denmark, United Kingdom
STATA version 11 is a software package for statistical analysis, data management, and graphics. It provides a wide range of statistical tools and functions for researchers, analysts, and professionals in various fields. The core function of STATA version 11 is to perform advanced statistical analysis and modeling on data.
4
Spss for windows statistical package by IBM
Sourced in United States
SPSS for Windows is a statistical software package developed by IBM. It provides a comprehensive set of tools for data analysis, including descriptive statistics, advanced statistical modeling, and data visualization. The software is designed to handle a wide range of data types and is commonly used in academic, business, and research settings.
5
Pretreatment module by Agilent Technologies
Sourced in United States
The Pretreatment module is a laboratory equipment designed to prepare samples for subsequent analysis. It performs essential sample preparation steps, such as dilution, filtration, or extraction, to ensure the sample is in the appropriate state for analysis by other analytical instruments.
6
Dmem f12 by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Denmark, Israel, Macao, Ireland, Netherlands, Austria, Hungary, Holy See (Vatican City State), Sweden, Brazil, Argentina, India, Poland, Morocco, Czechia
DMEM/F12 is a cell culture medium developed by Thermo Fisher Scientific. It is a balanced salt solution that provides nutrients and growth factors essential for the cultivation of a variety of cell types, including adherent and suspension cells. The medium is formulated to support the proliferation and maintenance of cells in vitro.
7
Spss statistic by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Italy, Poland, India, Canada, Switzerland, Spain, China, Sweden, Brazil, Australia, Hong Kong
SPSS Statistics is a software package used for interactive or batched statistical analysis. It provides data access and management, analytical reporting, graphics, and modeling capabilities.
8
Facscalibur by BD
Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Belgium, Switzerland, Singapore, Uruguay, Australia, Spain, Poland, India, Austria, Denmark, Netherlands, Jersey, Finland, Sweden
The FACSCalibur is a flow cytometry system designed for multi-parameter analysis of cells and other particles. It features a blue (488 nm) and a red (635 nm) laser for excitation of fluorescent dyes. The instrument is capable of detecting forward scatter, side scatter, and up to four fluorescent parameters simultaneously.
9
Eswab by Copan
Sourced in Italy, United States, Denmark, United Kingdom
The ESwab is a specimen collection and transport system designed for the collection, transport, and preservation of clinical specimens. It consists of a flocked swab and a tube containing a modified liquid Amies medium. The ESwab is intended to maintain the viability of aerobic, anaerobic, and fastidious microorganisms during transport to the laboratory for analysis.
10
Trypan blue by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, Canada, Brazil, France, Spain, Poland, Sao Tome and Principe, China, Belgium, Japan, India, Australia, Macao, Sweden, Hungary, Portugal, Singapore, Switzerland
Trypan blue is a vital dye used in cell biology and biochemistry. It is a blue dye that can selectively color dead cells or cells with damaged membranes blue, while live cells with intact cell membranes are not colored. This property makes trypan blue a useful tool for distinguishing viable from non-viable cells in a cell suspension.

More about "Hormonal Contraception"

Hormonal contraception is a broad term that encompasses a variety of methods for preventing pregnancy through the use of synthetic hormones.
These methods include oral contraceptives (birth control pills), contraceptive patches, vaginal rings, contraceptive injections, implants, and intrauterine devices (IUDs).
Hormonal contraception works by preventing ovulation, thickening the cervical mucus to block sperm, and/or thinning the uterine lining to inhibit implantation.
The effectiveness of hormonal contraception can be influenced by factors such as the type of hormone, the dosage, and individual variations in metabolism and absorption.
Contraceptive protocols may involve the use of estrogen and progestin, progestin-only, or a combination of both.
The SPSS version 25 statistical software package, STATA version 11, and SPSS for Windows can be utilized to analyze data related to hormonal contraception research, including the efficacy, safety, and user preferences of different methods.
Researchers may also employ tools like the Pipelle aspirator, a device used for endometrial sampling, and the FACSCalibur flow cytometer for cell analysis.
The DMEM/F12 culture medium and Trypan blue dye may be used in in vitro studies of hormonal contraceptive methods.
The ESwab system can be used for sample collection and transportation in clinical studies.
Pretreatment modules in research software may help researchers design and analyze studies on hormonal contraception, while SPSS Statistics can be used for advanced statistical analysis.
By leveraging these tools and resources, researchers can gain deeper insights into the complex field of hormonal contraception, ultimately leading to the development of more effective and innovative contraceptive solutions.